Clinical Trial Update: Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dosing and safety of BAY 2433334, an oral FXIa inhibitor, in patients after acute non-cardioembolic ischemic stroke; study completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cardioembolic Ischemic Stroke

Drugs mentioned

• BAY 2433334 (BAY 2433334)

Snippet

Sponsor: Bayer | Conditions: Acute Non-cardioembolic Ischemic Stroke | Phase 2 | Status: COMPLETED | Results posted: 2023-04-19